Introduction
============

*Vibrio parahaemolyticus* is a Gram-negative halophilic bacterium that lives in estuarine, marine and coastal surroundings. It is one of the leading causes of human food borne gastroenteritis due to consumption of raw or under-cooked seafood ([@B66]; [@B56]; [@B68]), and is also one of the major threats in aquaculture ([@B57]). *V. parahaemolyticus* can cause acute hepatopancreas necrosis disease (AHPND) in shrimp and is one of the major pathogens of cultured mud crabs ([@B63]; [@B69]).

*Vibrio parahaemolyticus* secretes virulence factors to establish successful infection in the host ([@B5]; [@B31]). Virulence factors that contain free thiol-groups (cysteine residues) require disulfide bonds for proper folding and function. Studies of oxidoreductases are therefore important for understanding bacterial pathogenesis and for developing novel therapeutics ([@B15]). Disulfide bond formation pathways in Gram-negative bacteria have been well studied in *Escherichia coli* ([@B23]; [@B9]). Disulfide bond formation protein A, DsbA, introduces disulfide bonds into proteins between consecutive cysteine residues as they pass through the inner membrane translocation system ([@B1]; [@B2]; [@B23]).

The Dsb redox system plays a pivotal role in the virulence of many pathogens ([@B4]; [@B15]; [@B50]; [@B51]; [@B35]). *Francisella tularensis* requires the DsbA redox system to promote the proper folding of virulence proteins ([@B50]; [@B51]). *Pseudomonas aeruginosa* DsbA is required for the expression of elastase, exotoxin A, protease IV, and is also required for the formation of a functional type III secretion system ([@B4]; [@B13]). *Serratia marcescens* DsbA is required for virulence and for proper deployment of the T6SS ([@B35]). We previously found that DsbA is indispensable to *Vibrio cholerae* pathogenesis. A *dsbA* deletion mutant of *V. cholerae* did not colonize the intestine because the expression of the master virulence gene regulator ToxT was abolished in the *dsbA* deletion mutant ([@B65]; [@B64]).

Here, we investigated the role of *V. parahaemolyticus* DsbA in pathogenesis. Two DsbA genes are predicted to be encoded in the *V. parahaemolyticus* genome. We analyzed the reductase activities and the redox potential of the purified DsbA proteins and characterized the virulence properties of single and double *dsbA* mutants. Deleting the dsbA genes affected *V. parahaemolyticus* virulence factor expression at the post-translational level.

Materials and Methods {#s1}
=====================

Bacterial Strains, Plasmids, and Media
--------------------------------------

The bacterial strains, plasmids, and oligonucleotides used in this study are summarized in [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}. All *V. parahaemolyticus* strains used in this study were derived from the HZ strain, a clinical isolate from the Zhejiang Provincial Center for Disease Control and Prevention, Zhejiang, China ([@B67]). *Escherichia coli* strains DH5α, BL21, and CC118λpir were used for general manipulation of plasmids, prokaryotic expression of proteins, and mobilization of plasmids into *V. parahaemolyticus*, respectively. The bacterial strains were grown at 37°C in Luria-Bertani (LB) broth with 1% NaCl ([@B54]) (for *E. coli*) or LB-NaCl (for *V. parahaemolyticus*) which is LB broth supplemented with 3% NaCl containing appropriate antibiotics. Plasmids for overexpressing VpDsbAs or VpDsbB or other proteins in *V. parahaemolyticus* were constructed by cloning the PCR-amplified coding regions into pBAD24Cm ([@B12]) and introduced into *V. parahaemolyticus* by conjugation with the helper strain of CC118λpir ([@B67]). Plasmids for overexpressing VpDsbAs in *E. coli* were constructed by cloning the coding regions into pacyc177 which has been modified to obtain an arabinose operon ([@B6]) and introduced into *E. coli* strain by electroporation ([@B54]).

###### 

Bacterial strains and primers used in this study.

  Strain                          Relevant characteristics                                                            References
  ------------------------------- ----------------------------------------------------------------------------------- ------------
  *V. parahaemolyticus* strains                                                                                       
  HZ                              Wild type (WT), clinical strain                                                     [@B67]
  YA1                             Δ*VpdsbA1, VpdsbA1* (*vp3054*) deletion                                             This study
  YA2                             Δ*VpdsbA2, VpdsbA2* (*vpa1271*) deletion                                            This study
  YA3                             Δ*VpdsbA1/2, VpdsbA1* and *VpdsbA2* deletion                                        This study
  YA4                             Δ*tdhAS, tdhA* (*vpa1314*) and *tdhS* (*vpa1378*) deletion                          This study
  YA5                             Δ*tdhAS/vp1696, tdhA*, *tdhS* and *VP1696* deletion                                 This study
  YA6                             Δ*tdhAS/vtrA, tdhA*, *tdhS* and *vtrA* (*vpa1332*) deletion                         This study
  ZT1                             Δ*tdhAS/vtrA/VpdsbA1/2, tdhA*, *tdhS*, *vtrA, VpdsbA1* and *VpdsbA2* deletion       This study
  ZT2                             Δ*tdhAS/VP1696/VpdsbA1/2, tdhA*, *tdhS*, *VP1696, VpdsbA1* and *VpdsbA2* deletion   This study
  ZT3                             Δ*VpdsbA1, VpdsbA1* deletion containing P*~BAD~*-VpdsbA1                            This study
  ZT4                             Δ*VpdsbA2, VpdsbA2* deletion containing P*~BAD~*-VpdsbA2                            This study
  ZT5                             Δ*VpdsbA1, VpdsbA1* deletion containing P*~BAD~*-VpadF-cFLAG                        This study
  ZT6                             Δ*VpdsbA2, VpdsbA2* deletion containing P*~BAD~*-VpadF-cFLAG                        This study
  ZT7                             Δ*VpdsbA1/2, VpdsbA1* and *VpdsbA2* deletion containing P*~BAD~*-VpadF-cFLAG        This study
  ZT8                             Δ*VpdsbA1, VpdsbA1* deletion containing P*~BAD~*-MAM7-cFLAG                         This study
  ZT9                             Δ*VpdsbA2, VpdsbA2* deletion containing P*~BAD~*-MAM7-cFLAG                         This study
  ZT10                            Δ*VpdsbA1/2, VpdsbA1* and *VpdsbA2* deletion containing P*~BAD~*-MAM7-cFLAG         This study
  *Escherichia coli* strains                                                                                          
  DH5α                            *E. coli* for cloning strain                                                        [@B14]
  BL21                            *E. coli* for protein expression and purification strain                            [@B25]
  CC118λpir                       *E. coli* for mobilization of plasmids into *V. parahaemolyticus*                   [@B67]

###### 

Primer sequences used for cloning in this study.

  Cloning            Primer sequence (5′→3′)
  ------------------ ---------------------------------------------------
  P*~BAD~-VpdsbA1*   F: CCGGAATTCATGAAAAAACTGTTCGCACTGTT
                     R: CATTGCTGCAGTTATTTTAGCGTTAGCAAGTAGTTCAC
  P*~BAD~-VpdsbA2*   F: GCTCTAGAGGGCTAGCAGGAGGAATTCATG
                     R: ACATGCATGCTTATAGCGTTAGCAGATAGTTCACCAATTC
  *VpdsbA1* dele     P1: CGCGGATCCCAATTTACCGATGAAGAGCGC
                     P2: CAGGAACTACTTCAAGATCCAATACTTTGTAATGTT
                     P3: GATCTTGAAGTAGTTCCTGCGGTTATCGTAAATAAC
                     P4: CGAGCTCTTAACGCTTCTTTTGTGATCCTC
  *VpdsbA2* dele     P1: CGCGGATCCAAACACATCGGTCACCCAAAG
                     P2: GGACGTTGAGAAAGGCGTTCCTGGCGTC
                     P3: AGGAACGCCTTTCTCAACGTCCAACACTTTG
                     P4: CGAGCTCCATTTGGAACGTAAGCATCTGC
  *vp1314* dele      P1: GAATTCCTGCAGCCCGGGGGATCCCTGAATTAGTAGAG TTAATC
                     P2: CATTTTACTTGGTCGAACAACAAACAATATCTCATCAG
                     P3: TGTTGTTCGACCAAGTAAAATGTATTTGGATGAAAC
                     P4: CTAAAGGGAACAAAAGCTGGAGCTCCTACCGCTAAATGC
  *vp1378* dele      P1: GAATTCCTGCAGCCCGGGGGATCCGTGGAAACAAGGCAAGC
                     P2: CATTTTACTTGGTCGAACAACAAACAATATCTCATCAG
                     P3: TGTTGTTCGACCAAGTAAAATGTATTTGGATGAAAC
                     P4: CTAAAGGGAACAAAAGCTGGAGCTCGTCTGATATCCGT GAAC
  *vp1696* dele      P1: GAATTCCTGCAGCCCGGGGGATCCGTGTGGTTTCGA TGTCGTC
                     P2: GTTTACAAAGCGCGCCGAACAGTTCGCATGTTC
                     P3: CTGTTCGGCGCGCTTTGTAAACGTGCAGTACTG
                     P4: CTAAAGGGAACAAAAGCTGGAGCTCGCTGATCCTTTGT TGCTAC
  *vpa1332* dele     P1: CGCGGATCCCTATTATGTTTAAATCCACCATCTCCTG
                     P2: TTGTTTTATCCAAGGCGAGGAGCACGAGATG
                     P3: CCTCGCCTTGGATAAAACAATATCTTTTAGC
                     P4: CGCGGATCCGGCTTGCTGCAGACGGTATTTAG
  T7-VpDsbA1         P1: CATGCCATGGCGCAATTCAAAGAAGG
                     P2: CCCAAGCTTTTTTAGCGTTAGCAAGTAGTTCACC
  T7-VpDsbA2         P1: GAATTCCATATGGCTCAATTTGAAGAAGGTAAAC ACTAC
                     P2: CCCAAGCTTTTAGTGATGATGATGATGATGTAGCGTTAGCAG
  T7-VPA1314         P1: CATGCCATGGGCTTTGAGCTTCCATCTGTCCCTTTTC
                     P2: CCCAAGCTTTTGTTGATGTTTACATTCAAAAAACG

Construction of the *dsbA* and *dsbB* Mutants
---------------------------------------------

In-frame deletion strains used in this study were described in previous publications ([@B67]; [@B22]). In-frame deletions of *VpdsbA1* (*vp3054*), *VpdsbA2* (*vpa1271*)*, VpdsbB* (*vp2073*) or *EcDsbA* were constructed by cloning the regions flanking the target genes into suicide vector pDS132 ([@B49]) containing a *sacB* counter selectable marker ([@B41]). The resulting plasmids were introduced into *V. parahaemolyticus* or *E. coli* by conjugation ([@B3]; [@B67]) and deletion mutants were selected for double homologous recombination events ([@B24]).

Zebrafish Virulence Evaluation
------------------------------

Zebrafish virulence assays were designed based on a previous publication ([@B45]). All animal experiments were carried out in strict accordance with the animal protocols that were approved by the Institutional Animal Care and Use Committee of Zhejiang A&F University (Permit Number: ZJAFU/IACUC_2011-10-25-02). Care and feeding of zebrafish followed established protocols^[1](#fn01){ref-type="fn"}^. Zebrafish were obtained from a commercial supplier between 5 and 6 months old and were raised at our animal facility at Zhejiang A&F University for at least 2 weeks before challenge experiments following previously published protocols ([@B45]). For challenge experiments, zebrafish were injected intraperitoneally using a repeater dispenser (Hamilton \#83700) and a 33 gauge needle (Hamilton 1750LTSN, 33/0.3759/PT4) following previously published protocols ([@B30]). Ten zebrafish per group were inoculated with each strain at a concentration of 10^7^ cfu 10 μl^−1^ of the inoculum and observed every 4 or 8 h for 48 h. Control fish injected with 10 μl PBS were included with each experiment. Experiments were repeated at least once. Tris-buffered tricaine at a concentration of 320 μg ml^−1^ was used to kill the fish on completion of the experiment. All aquaria and water were disinfected with 20% sodium hypochlorite after each experiment. Filters from air pumps were sterilized by autoclaving.

DsbA Cloning, Expression, and Purification
------------------------------------------

*Vibrio parahaemolyticus VpdsbA1*, *VpdsbA2* or *VPA1314* genes without the signal peptide sequence were amplified from the genomic DNA which was purified by QIAamp DNA Mini Kit (Qiagen) from bacterial culture. The PCR products without the signal peptide sequence were inserted into a modified pET-28a (Novagen, Inc.) vector encoding an N-terminal His~6~ tag. *E. coli* BL21(DE3)/pLysS ([@B25]) cells were transformed with the plasmid containing the target gene and transformed cells were used for protein expression by autoinduction ([@B58]). Proteins were expressed and purified on nickel columns according to the manufacturer's instructions (Invitrogen).

Antibody Preparation
--------------------

Ten milligrams of each protein, VpDsbA1, VpDsbA2, and VPA1314 (TDH) purified as described above were used as antigens, and then sent to GenScript Inc. for polyclonal antibodies preparation by immunizing rabbits. Antibody effectiveness was detected by Western blotting of each specific purified protein a week after the fourth immunization.

Insulin Reduction Assay
-----------------------

The protein disulfide reductase activity of VpDsbA was measured *in vitro* using the insulin-reduction assay in the presence of dithiothreitol (DTT) ([@B17]). Each DsbA protein (10 μM) was mixed with buffer consisting of 100 mM sodium phosphate, 2 mM ethylenediaminetetraacetic acid (EDTA), 0.33 mM DTT. Insulin (170 μM) was added immediately before measurements were made. Insulin reduction by DTT was monitored spectrophotometrically at 650 nm.

Redox Potential Determination
-----------------------------

VpDsbA redox potential assays were performed essentially as described by [@B62]. VpDsbA (2 μM) was incubated in fully degassed buffer consisting of 100 mM sodium phosphate, 1 mM EDTA pH 7.0 containing 1 mM oxidized glutathione (GSSG; Sigma--Aldrich, United States) and a range of reduced glutathione (GSH) concentrations (0.1--2.0 mM) for 24 h at room temperature. After incubation, the reactions were stopped with 10% trichloroacetic acid (TCA) and the precipitated protein pellets were collected by centrifugation at 16,000 × *g* for 30 min at 4°C. The pellets were washed with 100% ice-cold acetone and dissolved in a buffer consisting of 50 mM Tris-HCl pH 7.0, 1% sodium dodecyl sulfate (SDS), 10 mM 4-acetamide-4′-maleimidylstilbene-2,2′-disulfonate (AMS) to label the free thiols. Separation of the reduced and oxidized forms was performed on 12% SDS-polyacrylamide gels under denaturing conditions. Gels were stained with Coomassie Brilliant Blue and scanned. The relative intensity of the reduced and oxidized forms was analyzed using ImageJ^[2](#fn02){ref-type="fn"}^. The fraction of the reduced protein was plotted against the ratio \[GSH\]^2^/\[GSSG\]. The equilibrium constant *K*~eq~ was calculated using the equation:
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where *R* is the fraction of reduced protein at equilibrium. The standard redox potential was calculated using the Nernst equation,
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where *E*^0′^~*GSH/GSSG*~ is the standard potential of −240 mV ([@B10]), *R* is the universal gas constant 8.314 J K^−1^mol^−1^, *T* is the absolute temperature in Kelvin, *n* is the number of electrons transferred, *F* is the Faraday constant 9.648 × 10^4^ C mol^−1^ and *K*~eq~ is the equilibrium constant.

Real-Time Quantitative PCR (RT-qPCR) Analysis
---------------------------------------------

Overnight cultures of *V. parahaemolyticus* WT or *dsbA* mutants were subcultured at a dilution of 1:100 in LB-NaCl medium and incubated without shaking at 37°C for 4 h. Total RNA was purified from bacterial cultures using TRIzol reagent (Invitrogen), DNase digestion and RNA reverse transcription was performed by using the PrimeScript RT reagent Kit with gDNA Eraser (TaKara). Quantitative real-time qPCR was performed in 20 μl reaction mixtures containing SYBR quantitative PCR mix (Toyobo) to measure the transcriptional levels of genes of interest using the Mx3000P PCR detection system (Agilent) with primers specific for tested genes. The 16s rRNA gene were used as internal controls in all reactions.

Spot Titers Cadmium Resistance
------------------------------

Cadmium resistance was performed to quantify the relative disulfide oxidase activity of the strains *in vivo* as described in [@B64]. Briefly, strains were grown overnight in LB and diluted 1:100 into fresh LB media with appropriate antibiotics. Strains were grown to mid-logarithmic phase at 37°C and serially diluted into phosphate buffer salt (PBS). A 5 μl aliquot of each dilution was plated onto LB plates with a cadmium gradient. Cells were grown at 37°C overnight. All spot titers were performed at least in triplicate.

Isothermal Titration Calorimetry
--------------------------------

Affinity and thermodynamics of binding between taurocholate (TC) and VpDsbA proteins were assessed by isothermal titration calorimetry (ITC) using a VP-ITC instrument (MicroCal^TM^, GE Healthcare) according to the protocols as described in [@B64]. Briefly, the sample cell was loaded with 1.5 ml of purified protein at 200 μM concentration in PBS. The syringe was filled with TC in the same buffer as that was used to dilute the proteins at a concentration of 4 mM. Titrations were conducted at 25°C using 25 consecutive injections of 10 μl each delayed by 300 s with a stirring speed of 307 rpm. As a control for background noise, titration of TC into a solution containing the buffer only was performed. The association constant (*K~a~* = 1/*K~d~*), free energy (ΔG), and enthalpy change (ΔH) and entropy change (ΔS) were calculated by fitting the data to a single-site binding model using the MicroCal Origin software (Origin 7.0 SR4 version7.0552β). Parameters reported include the mean ± SD across three replicates. The calculated *c*-value for these measurements is 12.

Motility Assay in Soft Agar
---------------------------

Motility assay was performed essentially on soft LB (for *E. coli* strains) or LB-NaCl (for *V. parahaemolyticus* strains) agar (0.25%) as described ([@B47]). *E. coli* or *V. parahaemolyticus* strains were grown overnight on LB or LB-NaCl agar and a single colony of each strain was inserted into soft agar by tooth pick and incubated at 37°C for 8--12 h. Motility was assessed by examining migration of bacteria through agar from the center toward the periphery of the colony. The diameter of the motility circle was analyzed using ImageJ (see text footnote 2).

VpDsbA Oxidized by VpDsbB Present in Membranes
----------------------------------------------

VpDsbA oxidized by VpDsbB *in vitro* was performed as previously described ([@B64]). *V. parahaemolyticus* strain Δ*dsbA* harboring a plasmid encoding VpDsbB under the control of an arabinose inducible promoter was cultured at 37°C with 200 rpm shaking in LB-NaCl medium until OD~600~≈0.5. 0.2% of arabinose was added and bacteria were kept cultured in the same conditions for another 16 h. Membranes were prepared according to [@B28]. Purified DsbA was reduced by incubation in 50 mM DTT for 10 min at 4°C. DTT was then removed by gel filtration on PD-10 Sephadex columns (GE). Reduced DsbA was stored at −80°C in the presence of 0.1 mM EDTA, pH 8.0. VpDsbB membrane suspension (1 mg/ml) was mixed with 10 mM ubiquinone 1 (UQ1) with or without different concentrations of TC as indicated in PBS. Reactions were started right after 2 mM of reduced VpDsbA was added. TCA (10%) was added at different time points to stop the reaction and protein was precipitated at 4°C overnight. Precipitated proteins were treated with AMS as described. Negative controls were the membrane of *V. parahaemolyticus* Δ*dsbA/dsbB*.

Cell Adhesion Assay
-------------------

Caco-2 cells (Sigma-Aldrich Inc.) were maintained in Dulbecco's Modified Eagle Medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS, Invitrogen) at 37°C in 5% CO~2~. Adhesion assays were carried out as previously described ([@B33]). Briefly, Caco-2 cells were infected with freshly prepared *V. parahaemolyticus* cultures of tested strains at a multiplicity of infection (MOI) of 10. As a control, bacterial cells were added to the empty wells of the cell culture plates and incubated for the same time as the binding experiment to determine the final total number of *V. parahaemolyticus* for the experiment. After 1 h infection, cells were washed three times with PBS and then lysed with 1% Triton X-100 at 37°C for 10 min. The cell lysates and control bacteria were serially diluted and plated on LB-NaCl agar. Attachment rate was calculated by dividing bound bacteria to the total bacterial load.

Kanagawa Hemolytic (KH) Activity Assay
--------------------------------------

Kanagawa hemolytic (KH) hemolytic activity was determined as described in [@B7]. Briefly, Wagatsuma blood agar (WBA) ([@B7]) contained 10% washed rabbit erythrocytes was prepared freshly before each assay. Bacteria from freshly prepared *V. parahaemolyticus* cultures of test strains were pelleted by centrifugation and washed with PBS. ∼10^8^ CFU in 10 μl bacterial suspension were dropped on WBA plates, and the result was observed after incubation for 24 h at 37°C. Well-defined, clear hemolysis around the bacterial growth was recorded and the hemolysis around area was analyzed using ImageJ (see text footnote 2).

Cytotoxicity Assay
------------------

The cytotoxic assays were performed as described previously ([@B16]). HeLa cells (Thermo Fisher Scientific Inc.) were seeded in 96-well plates. The overnight cultured strains were sub-cultured at the ratio 1:50 to the fresh LB-NaCl broth medium and grow at 37°C to OD~600~≈0.5. Bacteria were pelleted by centrifugation and washed with PBS, then suspended in two volumes of unsupplemented DMEM (DMEM without FBS). Before infection, HeLa cells were also washed with unsupplemented DMEM. Infection was performed at an MOI of 10. After infection, the release of lactate dehydrogenase (LDH) into the medium was quantified at each indicated time point with a CytoTox96 kit (Promega, Madison, WI, United States) used according to the manufacturer's instructions.

Statistical Analysis
--------------------

All data are presented as the mean ± SD of three determinations in each experimental condition. Statistical significance was determined using one-way ANOVA. *P* \< 0.05 was considered statistically significant.

Results
=======

*V. parahaemolyticus* Encodes Two *dsbA* Genes
----------------------------------------------

VP3054 (NP_799433.1) and VPA1271 (NP_800781.1) are predicted to be DsbA homologs in *V. parahaemolyticus*. The amino acid sequences of VP3054 and VPA1271 were compared and thioredoxin-fold molecular features were observed ([Figure 1A](#F1){ref-type="fig"}). Both VP3054 and VPA1271 show about 40% amino acid sequence identity to *E. coli* DsbA (EcDsbA), *Klebsiella pneumonia* DsbA (KpDsbA) or *Salmonella enterica* DsbA (SeDsbA), and the identities are even higher when compared to *V. cholerae* DsbA from (VcDsbA). VP3054 shows 79% identity to VcDsbA while VPA1271 is 59% identical ([Figure 1A](#F1){ref-type="fig"}). Both VP3054 and VPA1271 encode a DsbA-like domain, including a conserved CXXC active-site motif (CPHC in this case) and a putative *cis*Pro motif ([@B52]) ([Figure 1A](#F1){ref-type="fig"}). Comparison of loop sequences on the catalytic face of these DsbA proteins revealed that both the two DsbAs from *V. parahaemolyticus* should belong to Class-Ia DsbA ([@B40]; [@B59]). To differentiate these two proteins, we named VP3054 as VpDsbA1 and VPA1271 as VpDsbA2.

![VpDsbAs modulate *V. parahaemolyticus* virulence in zebrafish. **(A)** Amino acid alignment of VpDsbA1, VpDsbA2, VcDsbA, and EcDsbA. The red line indicates the conserved CXXC motif. Three loop sequences of L1, L2, and L3 are indicated as an orange, blue, and black line, respectively, and a red star indicates the predicted *cis*Pro. **(B)** *Top*, analysis of VpDsbA1 and VpDsbA2 expression level. *V. parahaemolyticus* WT, Δ*VpdsbA1*, Δ*VpdsbA2*, and Δ*VpdsbA1/2* were grown in LB-NaCl until OD~600~≈0.8. Cell lysates (1 mg) were separated by SDS-PAGE and VpDsbA1 or VpDsbA2 was detected by the Western blot using antiserum specific for either VpDsbA1 or VpDsbA2. Blot shown is representative of at least three separate experiments. *Bottom*, analysis of *VpdsbA1* and Δ*VpdsbA2* mRNA levels by qRT-PCR. RNA was purified from freshly prepared cultures grown in LB-NaCl. The % *dsbA* mRNA levels ± standard deviation (SD) were normalized to 16S RNA for each strain and relative to WT (set to 100%). ND, none detected. **(C)** Survival curves (Kaplan--Meier) of zebrafish following intraperitoneal challenges of *V. parahaemolyticus* WT, Δ*VpdsbA1*, Δ*VpdsbA2*, and Δ*VpdsbA1/2* strains.](fmicb-10-01103-g001){#F1}

We found that both *VpdsbA1* and *VpdsbA2* are expressed in *V. parahaemolyticus* ([Figure 1B](#F1){ref-type="fig"}), and mutating one gene did not appreciably affect the expression of the other gene. In a zebrafish infection model, Δ*VpdsbA1/2* had significantly reduced virulence while both Δ*VpdsbA1* and Δ*VpdsbA2* were as virulent as the wild type strain ([Figure 1C](#F1){ref-type="fig"}). Each mutant grew similarly to the wild-type strain in broth culture ([Supplementary Figure S1](#SM1){ref-type="supplementary-material"}). These results suggest that both VpDsbA1 and VpDsbA2 are functional in *V. parahaemolyticus* and they may function redundantly, because a virulence defect was only seen in the double mutant.

Redox Properties of VpDsbA1 and VpDsbA2
---------------------------------------

To investigate the enzyme activity of VpDsbA1 and VpDsbA2, we performed a standard reductase activity assay using folded insulin as the substrate and DTT as the electron donor ([@B17]). Insulin comprises A and B chains which are linked by two disulfide bonds, and the reduction of the disulfide bonds leads to B-chain precipitation, which can be monitored as an increase in absorbance at 650 nm. B chain precipitation and a consequent increase in the OD~650~ was measurable after 22 min with EcDsbA ([Figure 2A](#F2){ref-type="fig"}). B chain precipitation was observed after 15 min with VpDsbA1 and after 22 min with VpDsbA2. Insulin reduction was observed after 10 min with VcDsbA.

![Reductase activity and redox potential of VpDsbAs. **(A)** Insulin (170 μM) and 0.33 mM DTT was incubated with 10 μM of each DsbA protein. The reduction of insulin was measured by monitoring the increase in absorbance at OD~650~. Reaction without reductase protein is used as negative control (NC). **(B,C)** Characterization of the redox potential of VpDsbA1 **(B)** and VpDsbA2 **(C)**. Non-linear fit to the fraction of reduced VpDsbA at different ratios of reduced:oxidized glutathione. This fit was used to obtain the equilibrium constant *K*~eq~ and the redox potential \[calculated relative to the GSH/GSSG standard potential of --240 mV ([@B10])\]. The curve was fit to the averaged data from three replicate experiments.](fmicb-10-01103-g002){#F2}

To better characterize the redox properties of VpDsbA1 and VpDsbA2, we determined the standard redox potential of these two proteins relative to the redox potential of GSH/GSSG (−240 mV) ([@B10]). By calculating the fraction of reduced VpDsbA at different concentrations of \[GSH\]^2^/\[GSSG\], the equilibrium constants were determined ([Figure 2B,C](#F2){ref-type="fig"}). The *K*~eq~ for VpDsbA1 was 8.4[+]{.ul}0.06 × 10^−5^ M and VpDsbA2 was 1.2[+]{.ul}0.03 × 10^−4^ M. The corresponding redox potentials of VpDsbA1 and VpDsbA2 are −118 mV and −123 mV rat pH 7.0. Thus, VpDsbA1 is relatively oxidizing, with a redox-potential value similar to that of the thioredoxin-fold proteins, VcDsbA (*E*^0′^ = −116 mV) ([@B62]) and the redox-potential value of VpDsbA2 is similar to that of VcDsbA (*E*^0′^ = −122 mV) ([@B20]).

VpDsbAs Function as Oxidases in *V. parahaemolyticus*
-----------------------------------------------------

It was previously reported that *E. coli* Δ*dsbA* showed cadmium sensitivity due to the high affinity of Cd^2+^ for protein free thiols ([@B61]). We tested *V. parahaemolyticus dsbA* mutant cadmium sensitivity as an indicator of oxidase capacity. *V. parahaemolyticus* WT and mutants were grown in the presence of increasing concentrations of cadmium (0--1.25 mM). The wild type strain of *V. parahaemolyticus* grew on concentrations of up to 1 mM cadmium, but the Δ*VpdsbA1*, Δ*VpdsbA2*, and Δ*VpdsbA1/2* mutants were cadmium-sensitive ([Figure 3A](#F3){ref-type="fig"} and [Table 3](#T3){ref-type="table"}). These results suggest that both VpDsbA1 and VpDsbA2 possess oxidase activity.

![VpDsbA *in vivo* activity assay. **(A)** *V. parahaemolyticus* WT, Δ*VpdsbA1*, Δ*VpdsbA2*, and Δ*VpdsbA1/2* strains were tested in cadmium sensitivity assays by spotting 10^3^ cfu of each bacterial strain onto LB-NaCl containing increasing concentrations of cadmium (0--1.25 mM) in the presence or absence of 1 mM TC. **(B)** Motility assay of *V. parahaemolyticus dsb* mutants and *E. coli* Δ*EcdsbA* complemented with either EcdsbA, VpDsbA1, or VpDsbA2. **(C)** Quantification of the diameter of the motility circle of each strain shown in panel **(B)** was performed using ImageJ software. Graph represents percentages of each *V. parahaemolyticus dsb* mutant versus WT strain or *E. coli* Δ*EcdsbA* complemented with either VpDsbA1 or VpDsbA2 versus that with EcdsbA. Statistical analysis was calculated by one-way ANOVA. *n* = 3. ^∗∗^*P* \< 0.001.](fmicb-10-01103-g003){#F3}

###### 

Cadmium sensitivity assay of *V. parahaemolyticus* WT and mutant strains.

                 Mean cfu^b^ ± SD^c^            
  -------------- --------------------- -------- --------
  **−TC**                                       
  WT             46 ± 13               24 ± 5   0 ± 0
  Δ*VpdsbA1*     47 ± 8                17 ± 8   0 ± 0
  Δ*VpdsbA2*     56 ± 9                10 ± 2   0 ± 0
  Δ*VpdsbA1/2*   2 ± 1                 0 ± 0    0 ± 0
  CΔ*VpdsbA1*    72 ± 7                34 ± 6   10 ± 2
  CΔ*VpdsbA2*    74 ± 7                21 ± 4   0 ± 0
  **+TC**                                       
  WT             39 ± 4                26 ± 9   0 ± 0
  Δ*VpdsbA1*     29 ± 4                0 ± 0    0 ± 0
  Δ*VpdsbA2*     29 ± 1                0 ± 0    0 ± 0
  Δ*VpdsbA1/2*   0 ± 0                 0 ± 0    0 ± 0
  CΔ*VpdsbA1*    29 ± 3                19 ± 4   0 ± 0
  CΔ*VpdsbA2*    25 ± 3                3 ± 1    0 ± 0

a

The strains used were V. parahaemolyticus wild type (WT) and dsbA mutants, ΔVpdsbA1, ΔVpdsbA2, and ΔVpdsbA1/2, and the complementary strains CΔVpdsbA1 and CΔVpdsbA2 which contain P

BAD

-VpDsbA1 or P

BAD

-VpDsbA2, respectively.

b

10

3

cfu of each bacterial strain from the mid-log culture were spotted onto LB-NaCl containing 0.2% (wt/vol) of arabinose and increasing concentrations of cadmium in the presence (+TC) or absence (−TC) of 1 mM TC and incubated at 37°C for another 16 h. Colony-forming units (cfu) were quantified at each cadmium concentration.

c

Experiments were performed in triplicate.

d

Cadmium concentration (mM).

*E. coli* Δ*dsbA* or Δ*dsbB* were reported to be defective in motility because they fail to assemble flagella due to a lack of disulfide bonds in the P-ring protein (FlgI) ([@B8]). However, we did not observe the same motility defect in *V. parahaemolyticus dsb* mutants ([Figure 3B,C](#F3){ref-type="fig"}). To test if VpDsbA1 and VpDsbA2 can rescue this defect in *E. coli* Δ*dsbA*, we introduced VpdsbA1 or VpdsbA2 on plasmids with a low copy number replication origin under the control of the P*~BAD~* promoter in *E. coli* Δ*dsbA*. Both VpDsbA1 and VpDsbA2 were able to restore the motility of *E. coli* Δ*dsbA* ([Figure 3B,C](#F3){ref-type="fig"}).

Bile Salts Repress VpDsbAs Activity
-----------------------------------

When *V. parahaemolyticus* enters into the human body through the consumption of contaminated water or uncooked food, a set of virulence determinants controlled by a regulatory network are produced in response to the chemical signals present in the small intestine where it normally causes disease ([@B53]). *V. parahaemolyticus* uses bile salts to regulate virulence factor expression ([@B11]; [@B32]). Bile salts also induce virulence gene expression in *V. cholerae* by interfering with the redox reaction of DsbA proteins ([@B64]). We first investigated the interaction between the bile salt TC and VpDsbA1 and VpDsbA2 by using ITC. We found that both VpDsbA1 and VpDsbA2 can bind TC, with a *K~D~* of 131 ± 7 μM and 164 ± 11 μM, respectively ([Figure 4A](#F4){ref-type="fig"}). We also tested TrxA from *E. coli* binding to TC by ITC, but EcTrxA and TC did not show any specific interaction ([Supplementary Figure S2](#SM1){ref-type="supplementary-material"}) which indicated that the binding of VpDsbA1 or VpDsbA2 with TC is a specific interaction event.

![Bile salts inhibit VpDsbAs activity. **(A)** Bile salts interact with VpDsbA. ITC data titrating 4 mM of TC into 0.2 mM of tested proteins, VpDsbA1 (left) and VcDsbA2 (right). **(B)** Insulin reduction by VpDsbA1 or VpDsbA2 was inhibited in the presence of TC. Insulin (170 μM) and 0.33 mM DTT was incubated with 10 μM of VpDsbA, and 0.1 mM of TC were added at the beginning of reaction. The reduction of insulin was measured by monitoring the increase in absorbance at OD~650~. **(C)** Reduced VpDsbA oxidized by VpDsbB present in the membranes *in vitro*. Reduced VpDsbA (2 μM) was incubated with or without VpDsbB containing membranes and trapped with AMS after various incubation times. After incubation with VpDsbB membrane, VpDsbA (O) shifts to a lower molecular weight band. VpDsbA was detected using Western blot with an anti-VpDsbA antibody.](fmicb-10-01103-g004){#F4}

Insulin reduction mediated by either VpDsbA1 or VpDsbA2 was inhibited by TC ([Figure 4B](#F4){ref-type="fig"}). The cadmium sensitivity assay showed that *V. parahaemolyticus* was more sensitive to cadmium in the presence, than in the absence of TC ([Figure 3A](#F3){ref-type="fig"} and [Table 3](#T3){ref-type="table"}), indicating that TC might reduce the efficiency of disulfide bond formation catalyzed by VpDsbAs in the periplasm of *V. parahaemolyticus*. DsbA reductase activity correlates with DsbA reoxidation by DsbB ([@B52]). To test if VpDsbA activity inhibited by TC *in vivo* is because TC interferes with the reaction between VpDsbA and VpDsbB, we studied the oxidization of VpDsbA by VpDsbB *in vitro*. The oxidization of both VpDsbA1 and VpDsbA2 by the membrane protein VpDsbB was inhibited by TC *in vitro* ([Figure 4C](#F4){ref-type="fig"}).

VpDsbAs Impact *V. parahaemolyticus* Pathogenesis
-------------------------------------------------

*Vibrio parahaemolyticus* has evolved several regulatory networks that control the production of a wide range of virulence factors which enables them to cause disease in the host, including the thermostable direct hemolysin (tdh) and TDH related hemolysin (trh), adhesin, and secreted effectors ([@B68]; [@B33]). We found that *V. parahaemolyticus*Δ*VpdsbA1/2* exhibits reduced virulence in the zebrafish infection model ([Figure 1C](#F1){ref-type="fig"}). To understand why, we first investigated the effect of VpDsbAs on host cell adhesion ([@B33]). Deleting either *VpdsbA1* or *VpdsbA2* decreased *V. parahaemolyticus* attachment to Caco-2 epithelial cells ([Figure 5A](#F5){ref-type="fig"}). Several adhesion factors present at the surface of *V. parahaemolyticus* have been reported to be important in host cell binding, including MAM7 (Multivalent Adhesion Molecule 7) ([@B29]), MSHA pilus ([@B44]), PilA ([@B55]), and VpadF ([@B33]). To determine whether VpDsbAs are involved in maintaining the stability of these adhesion factors, we quantified the abundance of MAM7 (VP1611), MshA (VP2697), PilA (VP2523), and VpadF (VP1767). The abundance of VpadF, but not MAM7 was significantly reduced in the Δ*VpdsbA1/2* mutant but not in Δ*VpdsbA1* or Δ*VpdsbA2* single knock-out mutant ([Figure 5B](#F5){ref-type="fig"}) which indicates that either one of these two VpDsbA proteins is necessary for VpadF stability. The VpDsbAs had no effect on the transcription levels of all these adhesion factors ([Figure 5B](#F5){ref-type="fig"} and [Supplementary Figure S3](#SM1){ref-type="supplementary-material"}). These results indicate that the stability of VpadF depends on a functional DsbA protein present in the periplasm of *V. parahaemolyticus* which plays an important role in *V. parahaemolyticus* adhesion to epithelia cells.

![VpDsbAs is required in pathogenesis of *V. parahaemolyticus*. **(A)** Adhesion of *V. parahaemolyticus* WT, Δ*VpdsbA1*, Δ*VpdsbA2*, and Δ*VpdsbA1/2* and the complement strains to Caco-2 cells. Statistical analysis was calculated by one-way ANOVA. *n* = 3. ^∗∗∗^*P* \< 0.001. **(B)** *Top*, analysis of VpadF and MAM7 protein levels. *V. parahaemolyticus* WT, Δ*VpdsbA1*, Δ*VpdsbA2*, and Δ*VpdsbA1/2* containing P*~BAD~*-VpadF-cFLAG or P*~BAD~*-MAM7-cFLAG were grown in LB-NaCl until OD~600~≈0.8. Cell lysates (1 mg) were separated by SDS-PAGE and VpadF or MAM7 was detected by the Western blot using anti-FLAG monoclonal antibody (Sigma-Aldrich, United States). Blot shown is representative of at least three separate experiments. *Bottom*, analysis of *VpadF* and *MAM7* mRNA levels by qRT-PCR. RNA was purified from freshly prepared cultures grown in LB-NaCl. The relative mRNA levels ± SD were normalized to 16S RNA. **(C)** Hemolysis activity of *V. parahaemolyticus* WT, Δ*VpdsbA1*, Δ*VpdsbA2*, and Δ*VpdsbA1/2* strains on Wagatsuma blood agar. **(D)** Quantification of area of the hemolysis circle of each strain shown in panel **(B)** was performed using ImageJ software. Statistical analysis was calculated by one-way ANOVA. *n* = 3. ^∗^*^∗∗^P* \< 0.001. **(E)** *Top*, analysis of TDH protein level. *V. parahaemolyticus* WT, Δ*VpdsbA1*, Δ*VpdsbA2*, and Δ*VpdsbA1/2* and the complement strains were kept growing in LB-NaCl containing 1 mM of taurodeoxycholate acid (TDCA) at 37°C until 10% (vol/vol) trichloroacetic acid (TCA) was added. Protein samples were suspended in a buffered solution containing 100 mM Tris-HCl pH 7.5 and 1% (wt/vol) SDS and 1 mg of each sample was separated by SDS-PAGE and TDH was detected by the Western blot using anti-TDH antibody. Blot shown is representative of at least three separate experiments. *Bottom*, analysis of *vpa1314* mRNA levels by qRT-PCR. RNA was purified from freshly prepared cultures grown in LB-NaCl containing 1 mM of TDCA. The relative mRNA levels ± SD were normalized to 16S RNA compared with that of WT. **(F)** Quantification of band intensities from blot shown in panel **(E)** was performed using ImageJ software. Graph represents percentages of TDH compared with that of WT. Protein expression levels were normalized to that of WT. Data shown are averages of three independent experiments. Statistical analysis was calculated by one-way ANOVA. *n* = 3. ^∗^*P* \< 0.05, ^∗∗∗^*P* \< 0.001. **(G)** Cytotoxicity assay of *V. parahaemolyticus* mutant strains against HeLa cells by detecting the release of LDH into the medium at each indicated time. Parameters reported include the mean ± SD across three replicates.](fmicb-10-01103-g005){#F5}

*Vibrio parahaemolyticus* strains isolated from clinical samples are able to lyse human erythrocytes when plated on a high-salt media called Wagatsuma agar, a process termed the Kanagawa (KP) test ([@B43]). To determine whether VpDsbAs contribute to the β-hemolytic activity of *V. parahaemolyticus*, we performed the KP test with WT and the *dsbA* mutants. We found that the β-hemolytic activity significantly decreased when both *VpdsbA* genes are deleted ([Figure 5C,D](#F5){ref-type="fig"}). TDH is the major toxin that contributes to the β-hemolytic activity of *V. parahaemolyticus* ([@B18]; [@B42]). The mRNA level of TDH was not affected by VpDsbAs ([Figure 5E,F](#F5){ref-type="fig"}). However, the amount of TDH protein decreased significantly in the Δ*VpdsbA1* and Δ*VpdsbA1/2* mutants ([Figure 5E,F](#F5){ref-type="fig"}), suggesting that VpDsbA1 plays a major role in maintaining TDH stability.

*Vibrio parahaemolyticus* harbors two type III secretion systems (T3SS) encoded in chromosomes 1 (T3SS1) and 2 (T3SS2) ([@B34]). T3SS1 is responsible for cytotoxicity and T3SS2 is primarily involved in enterotoxicity, as well as in cytotoxic activity against some specific cell lines ([@B16]). To test whether VpDsbAs affect cytotoxicity of *V. parahaemolyticus* against HeLa cells, HeLa cell lysis was measured by monitoring the release of LDH after infection with *V. parahaemolyticus tdh*As and T3SS deletion mutant strains in the presence or absence of VpDsbAs. VtrA is the master regulator of T3SS2 in *V. parahaemolyticus*, so T3SS2 will stop working with *vtrA* deletion ([@B26]); and T3SS1 will lose function when the inner membrane protein VP1696 is deleted from the genome ([@B46]). Consistent with previous reports ([@B46]; [@B16]), T3SS1 of *V. parahaemolyticus* works dominantly in cytotoxicity of HeLa cells ([Figure 5G](#F5){ref-type="fig"}). After 6 h infection, HeLa cells were nearly completely lysed by *V. parahaemolyticus* T3SS2 mutant strains containing a functional T3SS1, but strains without VpDsbAs showed ∼40% less lysis ([Figure 5G](#F5){ref-type="fig"}). This suggests that VpDsbAs play an important role in epithelial cell infection through T3SS1. By assessing the transcription level and the secretion level of some major effectors and the activators of T3SS1, we found that VpDsbAs do not have a significant effect on the transcription of genes involved in T3SS1 activity ([Supplementary Figure S4](#SM1){ref-type="supplementary-material"}). However, the secretion efficiency of VPA0450 decreased in *dsbA* mutant compared with that in WT strain, while VP1683 was secreted more efficiently in the mutant strain under the conditions that we tested ([Supplementary Figure S5](#SM1){ref-type="supplementary-material"}). We did not figure out what's the mechanism that VpDsbAs work differently in the secretion of these two effectors, yet, this strongly suggests that VpDsbAs affect T3SS1 functions at the post-translational level.

Discussion
==========

DsbA participates in protein folding by introducing disulfide bonds into proteins secreted to the periplasm ([@B19]; [@B15]). In this study, we characterized the redox properties of two DsbA proteins from *V. parahaemolyticus* and investigated their essential role for several important virulence factors that affect *V. parahaemolyticus* pathogenesis.

Two DsbA genes, VpDsbA1 and VpDsbA2, are encoded on *V. parahaemolyticus* chromosomes 1 and 2, respectively. Both genes share high sequence similarity with that of VcDsbA and EcDsbA and contain the classical CXXC active-site motif and *cis*Pro motif ([Figure 1A](#F1){ref-type="fig"}), catalyzed insulin reduction *in vitro* ([Figure 2A](#F2){ref-type="fig"}), and introduced disulfide bonds to the proteins secreted to the periplasm of *V. parahaemolyticus in vivo* ([Figure 3A](#F3){ref-type="fig"}). Unlike *E. coli* or *V. cholerae*, the motility of which is mainly driven by one set of flagellar system, *V. parahaemolyticus* possesses dual flagellar systems, a single polar flagellum which propels the bacterium in liquid (swimming) and the lateral flagella which drive the bacterium move on the surface (swarming) ([@B38]; [@B39]). *V. parahaemolyticus dsb* mutant strains were still motile ([Figure 3B](#F3){ref-type="fig"}). We speculate that if the polar flagellum stops working, which might be the case in the *dsb* mutants, the lateral flagella will be activated and enable *V. parahaemolyticus* to remain motile ([@B36]; [@B37]).

Like *V. cholerae* which activates virulence production by sensing bile salts ([@B65]; [@B64]), *V. parahaemolyticus* also hijacks bile salts as an intestinal signal to regulate virulence production ([@B11]). *V. parahaemolyticus* activates T3SS2 gene expression by sensing bile salts taurodeoxycholate acid (TDCA; [@B53]). Here, we found that both VpDsbA1 and VpDsbA2 can bind TC and TC repressed disulfide bond formation in the periplasm of *V. parahaemolyticus* by inhibiting the reoxidation of VpDsbA1 or VpDsbA2 by VpDsbB ([Figure 4](#F4){ref-type="fig"}). Bile salts act as a stressor to bacteria that transit the intestinal tract, so it is reasonable to speculate that bile salts might regulate *V. parahaemolyticus* bile resistance by affecting the activity of the Dsb system.

This study also describes the essential role of the two DsbA proteins for several important virulence factors that affect *V. parahaemolyticus* pathogenesis. Both VpDsbA1 and VpDsbA2 are transcribed and expressed in *V. parahaemolyticus* under the conditions that we tested. *V. parahaemolyticus dsbA* mutants, especially the double mutant, showed defects in attachment to Caco-2 cells, β-hemolytic activity, and cytotoxicity against HeLa cells ([Figure 5](#F5){ref-type="fig"}). All the mutants of Δ*VpdsbA1*,Δ*VpdsbA2*, and Δ*VpdsbA1/2* showed defects in attachment to Caco-2 cells compared with that of the wild type strain ([Figure 5A](#F5){ref-type="fig"}), however, the amount of adhesion factor VpadF decreased dramatically only in Δ*VpdsbA1/2* mutant and either VpDsbA1 or VpDsbA2 protein alone was sufficient for VpadF stability ([Figure 5B](#F5){ref-type="fig"}). All the other adhesion factors that we tested in this study are not affected by VpDsbA1 or VpDsbA2. This might indicate that some other unknown adhesion factors which are required VpDsbAs to fold correctly also contribute to the adhesion of *V. parahaemolyticus* to mammal cells. Compared to VpDsbA2, VpDsbA1 played a more important role in affecting the stability of virulence factor TDH ([Figure 5D](#F5){ref-type="fig"}) in *V. parahaemolyticus*. However, TDH can be oxidized by either VpDsbA1 or VpDsbA2 *in vitro* ([Supplementary Figure S6](#SM1){ref-type="supplementary-material"}). So VpDsbA1 and VpDsbA2 might work differently in maintaining TDH protein stability *in vivo*.

*Vibrio parahaemolyticus dsbA* mutant also showed dramatically reduced cytotoxicity against HeLa cells in the T3SS2 knock-out background (containing functional T3SS1) ([Figure 5E](#F5){ref-type="fig"}). Although the molecular mechanism by which VpDsbAs affect T3SS1 is not clear yet, it is reasonable to assume that the catalytic activity of VpDsbA to form a disulfide bond for the functional folding of various proteins is required for its virulence. *V. parahaemolyticus* T3SS1 is similar to the Ysc secretion system in *Yersinia* ([@B60]). *Yersinia pestis* DsbA is required for the formation of a ring-shaped structure in a type III secretion apparatus to secrete virulence effectors ([@B21]). Like *Yersinia*, the DsbA proteins of *V. parahaemolyticus* might also be required for the formation of the type III secretion apparatus. VcDsbA from *V. cholerae* was reported to be indispensible for the pathogenesis of this organism. VcDsbA is required for the functional maturation of secreted virulence factors in *V. cholerae* ([@B48]; [@B19]). VcDsbA is also essential for the homodimerization of TcpP to activate virulence gene expression in *V. cholerae* ([@B65]; [@B64]). VtrA, which is the master regulator of T3SS2 genes in *V. parahaemolyticus*, adopts the same topology and function as TcpP ([@B53]). The *dsbA* mutants did not show a defect in the cell invasion assay; on the contrary, the efficiency of invasion to HeLa cells was increased without VpDsbA ([Supplementary Figure S7](#SM1){ref-type="supplementary-material"}). We have checked the mRNA level of some T3SS2 relevant genes, *vpa1321*, *vpa1327*, *vpa1332*, *vpa1346*, *vpa1348* and *vpa1370* all of which have been reported to be important for T3SS2 function ([@B5]; [@B27]). We found that in the presence of TDCA, the mRNA level of all these tested genes in *dsbA* mutant did not show much difference from that of WT ([Supplementary Figure S8](#SM1){ref-type="supplementary-material"}). All these indicate that VpDsbAs might somehow affect T3SS2 function through an unknown mechanism.

Overall, this study describes the roles of DsbA in host cell adhesion, cytotoxicity, and β-hemolytic activity, which suggests that VpDsbAs could be a potential target for the development of antibacterial compounds to control *V. parahaemolyticus* infections.
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